These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 17373269)

  • 1. [Issues related to iron replacement in dialyzed patients].
    Kessler M
    Nephrol Ther; 2006 Sep; 2 Suppl 4():S266-73. PubMed ID: 17373269
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous iron versus erythropoiesis-stimulating agents: friends or foes in treating chronic kidney disease anemia?
    Kalantar-Zadeh K; Streja E; Miller JE; Nissenson AR
    Adv Chronic Kidney Dis; 2009 Mar; 16(2):143-51. PubMed ID: 19233073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between transferrin receptor-ferritin index and conventional measures of iron responsiveness in hemodialysis patients.
    Chen YC; Hung SC; Tarng DC
    Am J Kidney Dis; 2006 Jun; 47(6):1036-44. PubMed ID: 16731299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Monitoring iron status in end-stage renal disease patients on hemodialysis.
    Rafi A; Karkar A; Abdelrahman M
    Saudi J Kidney Dis Transpl; 2007 Mar; 18(1):73-8. PubMed ID: 17237895
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravenous iron supplementation for the treatment of anaemia in pre-dialyzed chronic renal failure patients.
    Mircescu G; Gârneata L; Capusa C; Ursea N
    Nephrol Dial Transplant; 2006 Jan; 21(1):120-4. PubMed ID: 16144853
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [How do we optimally evaluate iron stores in dialyzed patients treated with erythropoiesis stimulating agent?].
    Kessler M; Salignac S; Aimone-Gastin I
    Nephrol Ther; 2006 Sep; 2 Suppl 4():S261-5. PubMed ID: 17373268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive vision for intravenous iron therapy.
    Coyne DW
    Am J Kidney Dis; 2008 Dec; 52(6 Suppl):S14-20. PubMed ID: 19010257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Helicobacter pylori does not contribute to iron deficiency in hemodialysis patients].
    López T; Almirall J; Calvet X; Quesada M; Sanfeliú I; Segura F; García M
    Nefrologia; 2006; 26(6):673-8. PubMed ID: 17227244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The challenges of using serum ferritin to guide i.v. iron treatment practices in patients on hemodialysis with anemia.
    Easom A
    Nephrol Nurs J; 2006; 33(5):543-51; quiz 552-3. PubMed ID: 17044438
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Treatment of renal anemia with iron in hemodialysis patients in General Hospital Bjelovar].
    Lovcić V; Vujić J; Basić-Jukić N; Janković RI; Kurtović I; Dzapo M; Lovcić P
    Acta Med Croatica; 2011 Oct; 65 Suppl 3():45-8. PubMed ID: 23120815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of current intravenous iron preparations for the management of iron-deficiency anaemia: a review.
    Qunibi WY
    Arzneimittelforschung; 2010; 60(6a):399-412. PubMed ID: 20648931
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of C-reactive protein, reticulocyte haemoglobin content and inflammatory markers in iron and erythropoietin administration in dialysis patients.
    El-Khatib M; Duncan HJ; Kant KS
    Nephrology (Carlton); 2006 Oct; 11(5):400-4. PubMed ID: 17014552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron supplementation in haemodialysis--practical clinical guidelines.
    Silva J; Andrade S; Ventura H; Santos JP; Colaço S; Oliveira C; Ponce P
    Nephrol Dial Transplant; 1998 Oct; 13(10):2572-7. PubMed ID: 9794562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reticulocyte indices in patients with end stage renal disease on hemodialysis.
    Bhandari S; Turney JH; Brownjohn AM; Norfolk D
    J Nephrol; 1998; 11(2):78-82. PubMed ID: 9589378
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing iron status: beyond serum ferritin and transferrin saturation.
    Wish JB
    Clin J Am Soc Nephrol; 2006 Sep; 1 Suppl 1():S4-8. PubMed ID: 17699374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of reticulocyte haemoglobin content as marker of iron deficiency and predictor of response to intravenous iron in haemodialysis patients.
    Kim JM; Ihm CH; Kim HJ
    Int J Lab Hematol; 2008 Feb; 30(1):46-52. PubMed ID: 18190467
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Safety of parenteral iron therapy].
    Kessler M
    Nephrol Ther; 2006 Nov; 2 Suppl 5():S350-5. PubMed ID: 17373283
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low serum aluminum values in dialysis patients with increased bone aluminum levels.
    van Landeghem GF; D'Haese PC; Lamberts LV; Djukanovic L; Pejanovic S; Goodman WG; De Broe ME
    Clin Nephrol; 1998 Aug; 50(2):69-76. PubMed ID: 9725776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring the content of reticulocyte hemoglobin (CHr) as the progression of anemia in nondialysis chronic renal failure (CRF) patients.
    Tsuchiya K; Saito M; Okano-Sugiyama H; Nihei H; Ando M; Teramura M; Iwamoto YS; Shimada K; Akiba T
    Ren Fail; 2005; 27(1):59-65. PubMed ID: 15717636
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mature erythrocyte parameters as new markers of functional iron deficiency in haemodialysis: sensitivity and specificity.
    Bovy C; Gothot A; Delanaye P; Warling X; Krzesinski JM; Beguin Y
    Nephrol Dial Transplant; 2007 Apr; 22(4):1156-62. PubMed ID: 17237481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.